A randomised, multicentre, open label trial in patients with relapse or refractory acute myeloid leukemia to evaluate the antileukemic potential of the pharmaco-modulation of sequential high-dose cytarabine by fludarabine

Trial Profile

A randomised, multicentre, open label trial in patients with relapse or refractory acute myeloid leukemia to evaluate the antileukemic potential of the pharmaco-modulation of sequential high-dose cytarabine by fludarabine

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Nov 2015

At a glance

  • Drugs Fludarabine (Primary) ; Cytarabine; Idarubicin
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top